Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium + Olodaterol vs Fluticasone + Salmeterol in COPD (ENERGITO 2)
NCT03240575Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Forced Expiratory Volume in One Second Area Under the Curve From 0 to 24 Hours Response. Started Aug 2017; status: completed.
02
Drugs
tiotropiumolodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03240575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03240575.